English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Development of Ca2+ Responsive Contrast Agents for fMRI

Vibhute, S., Maier, M., Logothetis, N., & Angelovski, G. (2013). Development of Ca2+ Responsive Contrast Agents for fMRI. In COST TD1004 Action: Theranostics Imaging and Therapy: An Action to Develop Novel Nanosized Systems for Imaging: Guided Drug Delivery (pp. 43).

Item is

Basic

show hide
Genre: Meeting Abstract

Files

show Files

Locators

show
hide
Locator:
Link (Any fulltext)
Description:
-
OA-Status:

Creators

show
hide
 Creators:
Vibhute, SM1, 2, Author           
Maier, ME, Author
Logothetis, NK1, 2, Author           
Angelovski, G1, 2, Author           
Affiliations:
1Department Physiology of Cognitive Processes, Max Planck Institute for Biological Cybernetics, Max Planck Society, ou_1497798              
2Max Planck Institute for Biological Cybernetics, Max Planck Society, ou_1497794              

Content

show
hide
Free keywords: -
 Abstract: Magnetic resonance imaging (MRI) using contrast agents has been widely employed in diagnostic imaging and biomedical research. For this purpose, Gd3+ based complexes are commonly utilized. Recently, responsive (smart) contrast agents (SCAs) are being developed in order to aid better understanding of biological processes [1] They are able to report physiological or pathophysiological changes by altering the MR signal they produce. However the routine in vivo use of SCA is hampered due to challenges such as lack of tools to localize or quantify the agents, low MR signal, non-specific delivery etc. To overcome these challenges, one of the meaningful strategies is to conjugate SCA to various functional molecules such as dendrimers, nanoparticles, delivery vectors or fluorescent tags. The essential requirement when coupling SCAs to functional molecules is retaining their crucial physico-chemical properties in terms of MRI activity. Hence, the overall objective of our approach was to develop synthetic strategies in which modified DO3A chelator is appended with different linkers for further functionalization. Diverse synthetic strategies were successfully developed using liquid, as well as solid phase chemistry [2]. The SCA were modified and they still robustly response to Ca2+. The newly developed strategies open pathways to improve in vivo applicability of DO3A-based SCAs and to serve as better in vivo reporters in future fMRI experiments.

Details

show
hide
Language(s):
 Dates: 2013-09
 Publication Status: Published online
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: BibTex Citekey: VibhuteMLA2013
 Degree: -

Event

show
hide
Title: COST TD1004 Action: Theranostics Imaging and Therapy: An Action to Develop Novel Nanosized Systems for Imaging: Guided Drug Delivery
Place of Event: Athens, Greece
Start-/End Date: 2013-09-01 - 2013-09-03

Legal Case

show

Project information

show

Source 1

show
hide
Title: COST TD1004 Action: Theranostics Imaging and Therapy: An Action to Develop Novel Nanosized Systems for Imaging: Guided Drug Delivery
Source Genre: Proceedings
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: - Sequence Number: O33 Start / End Page: 43 Identifier: -